Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(03): 293-295
DOI: 10.4103/wjnm.WJNM_40_18
Case Report

Radioiodine (131I) therapy in a child with autism spectrum disorder: A complex and demanding task

Giovanni Bibbo
SA Medical Imaging, Women's and Children's Hospital, South Australia
,
Ian Kirkwood
SA Medical Imaging, Women's and Children's Hospital, South Australia
,
Victoria Sigalas
SA Medical Imaging, Women's and Children's Hospital, South Australia
,
Tracy Benger
SA Medical Imaging, Women's and Children's Hospital, South Australia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

In January 2017, an 11.5-year-old male child with autism was referred for radioiodine (RAI) therapy post total thyroidectomy for papillary thyroid carcinoma. The treatment required swallowing a RAI capsule and remaining isolated (48–72 h). Initially, obstacles to a successful treatment seemed insurmountable as he had complex needs and behavioral issues due to his autism, mild intellectual disability, and family environment. His mother was adamant that he would not be able to swallow the capsule and comply with the required isolation period. A multidisciplinary team was formed to explore options for successful treatment. Each option considered had its own risks and challenges. Behavioral therapy was considered to be the only possible option. It was pursued with regular, frequent contact between the child, his parents, and members of the team for counseling and behavioral modification, familiarization of the child with the staff, procedures, trial visits, and admission. The patient was successfully treated in October 2017.

Keywords

Autism spectrum disorder - isolation - lung metastases - papillary thyroid carcinoma - pediatric - radioiodine therapy

Financial support and sponsorship

Nil.




Publication History

Received: 12 April 2018

Accepted: 14 May 2018

Article published online:
22 April 2022

© 2019. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Higuchi Y, Motoki T, Ishida H, Kanamitsu K, Washio K, Oyama T, et al. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: A case report. BMC Cancer 2017;17:775.
  • 2 Jolly Kid Z. Versatile Playpen Extension Pack. Available from: https://www.onlinetoys.com.au/jolly-kidz-versatile-playpen-extension-pack.html. [Last accessed on 2017 Sep 04].
  • 3 Hänscheid H, Lassmann M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2009;16:1283-9.
  • 4 Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood 1969;33:649-61.
  • 5 Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171-82.